AHA GUIDELINES Bundle (free trial)

Atrial Fibrillation 2023 Update

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/387790

Contents of this Issue

Navigation

Page 86 of 131

87 8.2.3. Pharmacological Cardioversion COR LOE Recommendations 2a C-LD 1. For patients with AF, pharmacological cardioversion is reasonable as an alternative to electrical cardioversion for those who are hemodynamically stable or in situations when electrical cardioversion is preferred but cannot be performed. 2a A 2. For patients with AF, ibutilide is reasonable for pharmacological cardioversion for patients without depressed LV function (LVEF <40%). 2a A 3. For patients with AF, intravenous amiodarone is reasonable for pharmacological cardioversion, although time to conversion is generally longer than with other agents (8–12 hours). 2a A 4. For patients with recurrent AF occurring outside the setting of a hospital, the "pill-in-the-pocket" (PITP) approach with a single oral dose of flecainide or propafenone, with a concomitant AV nodal blocking agent, is reasonable for pharmacological cardioversion if previously tested in a monitored setting. 2b B-R 5. For patients with AF, use of intravenous procainamide may be considered for pharmacological cardioversion when other intravenous agents are contraindicated or not preferred.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Atrial Fibrillation 2023 Update